 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
||||||||||||||||||||||||||||||||||
 |
Cytyc Announces UK NHS London Region to Adopt ThinPrep Pap Test as Exclusive Cervical Screening Test
MARLBOROUGH, Mass., (Oct 14, 2004) - Cytyc Corporation today announced that the London Region of the National Health Service (NHS) intends to convert all cervical screening to the ThinPrep(R) Pap Test. The London Region is comprised of five sectors, which process approximately 650,000 Pap tests annually. In October 2003, the National Institute for Clinical Excellence (NICE) issued guidance recommending liquid-based cytology for cervical screening. This exclusive arrangement with the London Region represents a potential use of approximately 3.3 million ThinPrep Pap Tests over the five-year term of this contract. "We are extremely pleased with this decision. The thorough technical evaluation in the London Region was focused on the clinical performance of this test, and we commend those involved in this process," said Daniel J. Levangie, Cytyc's executive vice president. "The London Region is one of the largest regions in the UK and combined with the previously announced agreements in Scotland, the South West Region, and the South East (East) Region represent a total potential use of more than 1.75 million ThinPrep Pap Tests annually." About HologicHologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic’s core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C-arm and extremity MRI imaging for orthopedic applications. Cytyc’s products cover a range of cancer and women’s health applications, including cervical cancer screening, preterm birth screening, treatment of excessive menstrual bleeding, radiation treatment of patients with early-stage breast cancer. Forward-Looking Statements Forward-looking statements in this press release are made pursuant to the provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements relating to the Company's financial condition, operating results and future economic performance, and management's expectations regarding future growth opportunities, product acceptance and business strategy, constitute forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from those statements. Risks and uncertainties include, among others, dependence on key personnel and proprietary technology, uncertainty of product development efforts, product acceptance, management of growth, risks associated with litigation, the effective integration of acquired businesses and technologies, competition and competitive pricing pressures, risks associated with the FDA regulatory approval processes and any healthcare reimbursement policies, and other risks detailed in the Company's filings with the Securities and Exchange Commission, included under the heading "Certain Factors Which May Affect Future Results" in its 2003 Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q filed with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in Company expectations or events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
|
||||||||||||||||||||||||||||||||||||||||
 |
 |
||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||||||||||||||
| Home | Women's Health | R2 CAD | Suros Surgical | Skeletal Health | OEM Solutions | Customer Care Center | |||||||||||||||||||||||||||||||||||||||||
| Learning
Center | News & Events | Investor
Relations | About Hologic More Information | Locate Us | Terms of Use | Privacy Policy Copyright 2007 Hologic, Inc. All Rights Reserved. |
|||||||||||||||||||||||||||||||||||||||||